Fibrinolytic Agents

Name
Fibrinolytic Agents
Accession Number
DBCAT000013
Description

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Some drugs in this category may have indirect fibrinolytic/thrombolytic effects.

ATC Classification
Drugs
DrugDrug Description
AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
DefibrotideA mixture of single-stranded oligonucleotides used in the treatment of severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
SulodexideA drug used to treat chronic venous ulcers in the legs.
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
BrinaseNot Annotated
SaruplaseNot Annotated
StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
FibrinolysinFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
AstaxanthinInvestigated for use/treatment in eye disorders/infections, cancer/tumors (unspecified), and asthma.
UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
DicoumarolFor decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.
AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
Dermatan sulfateA medication indicated to prevent deep vein thrombosis.
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Cinnamic acidNot Annotated
Drugs & Drug Targets
DrugTargetType
AlteplaseFibrinogen alpha chaintarget
AlteplasePlasminogentarget
AlteplasePlasminogen activator inhibitor 1target
AlteplaseFibrinogen gamma chaintarget
ReteplaseFibrinogen alpha chaintarget
ReteplasePlasminogentarget
ReteplasePlasminogen activator inhibitor 1target
AnistreplaseFibrinogen alpha chaintarget
AnistreplasePlasminogentarget
AnistreplasePlasminogen activator inhibitor 1target
TenecteplaseUrokinase plasminogen activator surface receptortarget
TenecteplasePlasminogen activator inhibitor 1target
TenecteplaseFibrinogen alpha chaintarget
TenecteplasePlasminogen activator inhibitor 2target
TenecteplaseTetranectintarget
TenecteplaseKeratin, type II cytoskeletal 8target
TenecteplaseAnnexin A2target
TenecteplaseCalreticulintarget
TenecteplaseCalnexintarget
TenecteplaseProlow-density lipoprotein receptor-related protein 1target
TenecteplasePlasminogentarget
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
DefibrotideAdenosine receptor A1target
DefibrotideAdenosine receptor A2atarget
DefibrotideAdenosine receptor A2btarget
AncrodFibrinogen alpha chaintarget
SulodexideHeparin cofactor 2target
SulodexideAntithrombin-IIItarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
StreptokinasePlasminogentarget
StreptokinaseProteinase-activated receptor 1target
StreptokinaseCytosolic phospholipase A2enzyme
DesmoteplasePlasminogentarget
FibrinolysinPlasminogen activator inhibitor 1target
FibrinolysinUrokinase-type plasminogen activatortarget
AstaxanthinNF-kappa-B inhibitor alphatarget
UrokinaseUrokinase plasminogen activator surface receptortarget
UrokinasePlasminogentarget
UrokinasePlasminogen activator inhibitor 2target
UrokinasePlasminogen activator inhibitor 1target
UrokinasePlasma serine protease inhibitortarget
UrokinaseNidogen-1target
UrokinaseLow-density lipoprotein receptor-related protein 2target
UrokinaseSuppressor of tumorigenicity 14 proteintarget
UrokinaseMacrophage metalloelastaseenzyme
DicoumarolVitamin K epoxide reductase complex subunit 1target
DicoumarolNAD(P)H dehydrogenase [quinone] 1target
DicoumarolQuinone oxidoreductasetarget
DicoumarolCytochrome P450 2C9enzyme
DicoumarolSerum albumincarrier
DicoumarolCytochrome P450 2C6enzyme
DicoumarolCytochrome P450 2C11enzyme
PlasminogenTissue-type plasminogen activatorenzyme
PlasminogenUrokinase-type plasminogen activatorenzyme